Hansa Grows Cash Pile Ahead of Idefirix US Filing

European Launches Progressing Smoothly

The Swedish biotech has added another $40m to its coffers as it advances its potential ‘pipeline in a product’ for kidney disease.

Hansa keen to be a leader in kidney disease • Source: Shutterstock

With the European rollout for Idefirix progressing steadily, Hansa Biopharma AB is now preparing to go stateside and has raised fresh funds for the submission and potential US launch of the kidney transplant drug.

The Swedish company has completed a directed stock issue of around 7.85 million shares priced at SEK53.35 which has raised...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business